Prof. Ming Shi
✓ Available through China Expert Care
Professor and Chief Physician; recipient of the National Science Fund for Distinguished Young Scholars
Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center

Focus: Liver cancer treatment, including hepatic arterial infusion chemotherapy (HAIC) and combination therapy
Prof. Shi focuses on liver cancer. He was the senior author of a phase III trial comparing hepatic arterial infusion chemotherapy (HAIC) with transarterial chemoembolization (TACE) for large liver cancers, and of studies combining HAIC with targeted therapy and immunotherapy.
Conditions: Liver cancer
Selected publications
- Journal of Clinical Oncology, 2022 (senior author): Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. PubMed 34648352
- JAMA Oncology, 2019 (senior author): Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial. PubMed 31070690
- European Journal of Cancer, 2022 (senior author): Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial. PubMed 35981413
Profile on the hospital website: https://english.sysucc.org.cn/info_26.aspx?itemid=369
Request a written opinion from Prof. Ming Shi
Send your records. A medical coordinator will reply within 24 hours.
Start here